Journal articles: 'Lymphatic filariasis'

1

Bradley, J. E. "Lymphatic filariasis." Transactions of the Royal Society of Tropical Medicine and Hygiene 94, no. 3 (May 2000): 350. http://dx.doi.org/10.1016/s0035-9203(00)90351-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Andrade, Mauro. "Lymphatic Filariasis." Problems in General Surgery 18, no. 4 (December 2001): 79–83. http://dx.doi.org/10.1097/00013452-200112000-00013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Lourens, Gayle B., and Denise K. Ferrell. "Lymphatic Filariasis." Nursing Clinics of North America 54, no. 2 (June 2019): 181–92. http://dx.doi.org/10.1016/j.cnur.2019.02.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ichimori, Kazuyo. "MDA—Lymphatic Filariasis." Tropical Medicine and Health 42, no. 2SUPPLEMENT (2014): S21—S24. http://dx.doi.org/10.2149/tmh.2014-s03.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Voelker, R. "Fighting Lymphatic Filariasis." JAMA: The Journal of the American Medical Association 280, no. 22 (December 9, 1998): 1898—a—1898. http://dx.doi.org/10.1001/jama.280.22.1898-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Voelker, Rebecca. "Fighting Lymphatic Filariasis." JAMA 280, no. 22 (December 9, 1998): 1898. http://dx.doi.org/10.1001/jama.280.22.1898-jwm80009-2-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Streit, Thomas, and Jack Guy Lafontant. "Eliminating Lymphatic Filariasis." Annals of the New York Academy of Sciences 1136, no. 1 (July 25, 2008): 53–63. http://dx.doi.org/10.1196/annals.1425.036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Marsden, P. D. "Obstructive lymphatic filariasis." BMJ 306, no. 6870 (January 9, 1993): 136. http://dx.doi.org/10.1136/bmj.306.6870.136.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Simonsen, Paul E., and Mbutolwe E. Mwakitalu. "Urban lymphatic filariasis." Parasitology Research 112, no. 1 (December 13, 2012): 35–44. http://dx.doi.org/10.1007/s00436-012-3226-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Ramadhani, Tri. "Filariasis Limfatik di Kelurahan Pabean Kota Pekalongan." Kesmas: National Public Health Journal 3, no. 2 (October 1, 2008): 51. http://dx.doi.org/10.21109/kesmas.v3i2.229.

Full text

Abstract:

Filariasis limfatik masih merupakan masalah kesehatan masyarakat di Indonesia, khususnya di Kota Pekalongan. Hal ini ditandai dengan semakin meningkatnya angka mikrofilaria dan perluasan daerah dengan kasus filariasis limfatik.Tujuan penelitian adalah untuk mengetahui situasi filariasis limfatik diKelurahan Pabean Kota Pekalongan. Penelitian ini meliputi penduduk dan agent, dalam periode sekitar enam bulan (Juli-Desember 2007) dengan disain studi cross sectional. Pada penelitian ini dilakukan pemeriksaan klinis, survei darah jari dan identifikasi parasit penyebab filariasis limfatik. Hasil penelitian menunjukkan angka mikrofilaria (3,4) angka kesakitan akut filaria (0,4 %) yang tinggi, tetapi angka kesakitan kronis filaria rendah (0,00 %). Parasit penyebabfilariasis di Kelurahan Pabean adalah jenis Wuchereria bancrofti dengan kepadatan rerata mikrofilaria yang tinggi. Pengendalian filariasis limfatik di Kelurahan Pabean perlu dilakukan dengan pengobatan massal dan perubahan perilaku masyarakat.Kata kunci : Filariasis limfatik, kelurahan pabean, mikrofilaria.AbstractLymphatic filariasis is still being a public health problem in Indonesia, especially in Pekalongan district. This problem marked by the increasing rate of microfilaria and areas with lymphatic filariasis. The aim of this study is to know the epidemiologic situation of lymphatic filariasis in Pabean village Pekalongan district. The research was a cross-sectional design and covered host and agent within the period of July-Desember 2007. Data were collected through clinical survey of acute and chronic filariasis symptoms, blood survey and identification of lymphatic filariasis parasite. The result showed that microfilaremia rate was 3,4%, acute disease rate (ADR) 0,4 % and the chronic disease rate (CDR) 0,00 %. The average of microfilaria density in 1 ml blood was 465,63. Based onmicrofilaremia identification in the blood, the lymphatic filariasis agent in Pabean village is Wuchereria bancrofti type. Lymphatic filariasis control in Pabean village need to focused on Mass Drug Administration (MDA) and community behavior for healthy life.Key words : Lymphatic filariasis, pabean village, microfilaria.

APA, Harvard, Vancouver, ISO, and other styles

11

Meliyanie, Gusti, and Dicky Andiarsa. "Program Eliminasi Lymphatic Filariasis di Indonesia." Journal of Health Epidemiology and Communicable Diseases 3, no. 2 (May 18, 2019): 63–70. http://dx.doi.org/10.22435/jhecds.v3i2.1790.

Full text

Abstract:

Filariasis has been a public health problem in Indonesia for a long time and WHO has established this disease as a neglected disease which is a public health problem in the world, therefore a global filariasis elimination program that must be achieved in 2020. This article compiles some literature for writing references related to the development of global filariasis elimination and the progress of filariasis elimination in Indonesia particularly. Filariasis elimination program in Indonesia has been running at least 26 districts that have stopped implementing mass drug administration (MDA) from 239 endemic filariasisdistricts. The remaining districts are expected to have implemented MDAstart from 2015 so that the year 2020 is completed and verified also given predicates of filariasis elimination according to global target of filariasis elimination. Management-based and community-based research is important to determine the best model of elimination. There are still many challenges in increasing coverage, so that continuing education efforts on filariasis and the importance of treatment will motivate communities to play an active role in achieving maximum coverage targets, and national filariasis elimination targets can be achieved by 2020.

APA, Harvard, Vancouver, ISO, and other styles

12

Chow, C. K., J. S. McCarthy, R. Neafie, R. I. Cooper, T. Limpuangthip, P. Limpuangthip, and T. B. Nutman. "Mammography of lymphatic filariasis." American Journal of Roentgenology 167, no. 6 (December 1996): 1425–26. http://dx.doi.org/10.2214/ajr.167.6.8956571.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Taylor, M. J., and P. F. Turner. "Control of lymphatic filariasis." Parasitology Today 13, no. 3 (March 1997): 85–86. http://dx.doi.org/10.1016/s0169-4758(97)01001-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Bagcchi, Sanjeet. "India tackles lymphatic filariasis." Lancet Infectious Diseases 15, no. 4 (April 2015): 380. http://dx.doi.org/10.1016/s1473-3099(15)70116-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Taylor, Mark J., Achim Hoerauf, and Moses Bockarie. "Lymphatic filariasis and onchocerciasis." Lancet 376, no. 9747 (October 2010): 1175–85. http://dx.doi.org/10.1016/s0140-6736(10)60586-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Dean, Malcolm. "Egypt conquers lymphatic filariasis." Lancet Infectious Diseases 4, no. 5 (May 2004): 260. http://dx.doi.org/10.1016/s1473-3099(04)01023-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Babu, S., and T. B. Nutman. "Immunology of lymphatic filariasis." Parasite Immunology 36, no. 8 (August 2014): 338–46. http://dx.doi.org/10.1111/pim.12081.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Michael, Edwin, Mwele N. Malecela-Lazaro, and James W. Kazura. "Elimination of lymphatic filariasis." Lancet 368, no. 9533 (July 2006): 362–63. http://dx.doi.org/10.1016/s0140-6736(06)69100-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

KIMURA, EISAKU. "Elimination of Lymphatic Filariasis." Juntendo Medical Journal 61, no. 4 (2015): 378–88. http://dx.doi.org/10.14789/jmj.61.378.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Gogia, SB, Sathi, and Sangtin. "Elimination of lymphatic filariasis." National Medical Journal of India 29, no. 1 (2016): 37. http://dx.doi.org/10.4103/0970-258x.186922.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;. "Management of lymphatic filariasis." Inpharma Weekly &NA;, no. 735 (May 1990): 5–6. http://dx.doi.org/10.2165/00128413-199007350-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Orish, VernerN, and Henry Atawurah. "Giant scrotal lymphatic filariasis." Journal of Medicine in the Tropics 19, no. 2 (2017): 136. http://dx.doi.org/10.4103/jomt.jomt_20_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Vishwanath, Tejas, Angela Nagpal, Sunil Ghate, and Aseem Sharma. "Scrotal Lymphangiectasia with Penile Elephantiasis in Underlying Lymphatic Filariasis—Challenging the Diagnostic Mind! A Case Report." Dermatopathology 8, no. 1 (January 1, 2021): 10–16. http://dx.doi.org/10.3390/dermatopathology8010002.

Full text

Abstract:

Background: A plethora of diseases manifest as acquired genital lymphangiectasias which clinically manifest as superficial vesicles. They range from infections such as tuberculosis to connective tissue diseases such as scleroderma and even malignancy. Amongst infectious etiologies, lymphatic filariasis leads as the cause for lymphatic obstruction. Despite this, acquired lymphangiectasias due to this cause are not commonly reported. An unusual case of acquired scrotal lymphangiectasia secondary to filariasis is detailed in this paper with dermoscopic and histologic findings. Methods: A 65-year-old male farmer presented with multiple, asymptomatic vesicles over the scrotum with thickened scrotal and penile skin that had occurred for six years. He gave past history of intermittent fever and milky urine, was diagnosed with filariasis and treated with diethylcarbamazine for a year, four years previously. Systemic complaints abated but the peno-scrotal lesions did not. Results: Polarized dermoscopy revealed multiple skin-colored nodules and translucent pale blue lacunae over the scrotum. A few radially arranged linear irregular vessels were noted over the nodules. On histopathology, multiple ectatic lymphatics were noted in the mid and upper dermis with acanthosis and superficial perivascular lymphocytes. Peripheral smear revealed eosinophils; however, microfilariae could not be detected despite repeated diethylcarbamazine provocation and night smears being taken. The findings were compatible with acquired scrotal lymphangiectasia secondary to treated lymphatic filariasis. Local hygiene was advised; however, procedural treatments were refused by the patient. Conclusion: Herein, we report an unusual case of acquired scrotal lymphangiectasia of the scrotum secondary to treated lymphatic filariasis. Very few similar reports exist. To the best of our knowledge, dermoscopic features of this condition have not been elucidated before. This case, detailing an uncommon manifestation of a common disease (filariasis), demonstrates the importance of careful history taking and examination. This was especially so in the present case since only circumstantial evidence of filariasis was noted in investigations. There is a need to heighten awareness of this unusual condition amongst physicians especially if the patient hails from an area endemic for filariasis.

APA, Harvard, Vancouver, ISO, and other styles

24

Shrivastava, Saurabh, Anshita Gupta, and Chanchal Deep Kaur. "The Epitome of Novel Techniques and Targeting Approaches in Drug Delivery for Treating Lymphatic Filariasis." Current Drug Targets 21, no. 12 (September 18, 2020): 1250–63. http://dx.doi.org/10.2174/1389450121666200630111250.

Full text

Abstract:

Background: Lymphatic filariasis is a pervasive and life-threatening disease for human beings. Currently, 893 million people in 49 countries worldwide affected by lymphatic filariasis as per WHO statistics. The concealed aspects of lymphatic diseases such as delayed disease detection, inappropriate disease imaging, the geographical outbreak of infection, and lack of preventive chemotherapy have brought this epidemic to the edge of Neglected Tropical Diseases. Many medications and natural bioactive substances have seen to promote filaricidal activity against the target parasitic species. However, the majority of failures have occurred in pharmaceutical and pharmacokinetic issues. Objective: The purpose of the study is to focus on the challenges and therapeutic issues in the treatment of filariasis. The review brings novel techniques and therapeutic approaches for combating lymphatic filariasis. It also offers significant developments and opportunities for such therapeutic interventions. Conclusion: Through this review, an attempt has made to critically evaluate the avenues of innovative pharmaceuticals and molecular targeting approaches to bring an integrated solution to combat lymphatic filariasis.

APA, Harvard, Vancouver, ISO, and other styles

25

Kumar, Srivastava Pradeep. "Lymphatic Filariasis in India: A Journey towards Elimination." Journal of Communicable Diseases 52, no. 03 (September 30, 2020): 17–21. http://dx.doi.org/10.24321/0019.5138.202024.

Full text

Abstract:

The journey towards elimination of Lymphatic Filariasis (ELF) in India started with the deliberations in a meeting held at Delhi in 1996 recommending for pilot project of Mass Drug Administration (MDA) with DEC. Global Programme to Eliminate Lymphatic Filariasis (GPELF was launched in 2000 subsequent to World Health Assembly (WHA) resolution in 1997 making India as signatory. ELF campaign was launched on 5th June, 2004 with annual MDA in endemic districts. However, all the endemic districts could not initiate MDA due to logistics and preparedness issues, thus the journey initially experienced challenges of hurried start. Serious Adverse Events (SAE) and poor compliance were reported from many states which were tackled through advocacy and capacity building of health workers and community volunteers. MDA was managed with staggering of dates in different states and strong supervision helped in improving drug compliance. The improved reported drug coverage resulted in decline of microfilaria prevalence in many districts except some districts. India’s significant progress was recognised internationally as approximately 200 of 650 million population at risk of Lymphatic Filariasis (LF) was made free of risk by 2017 by passing Transmission Assessment Survey (TAS) though some districts could not clear TAS. Efforts to improve drug compliance were intensified and to achieve goal faster, MDA with three drug Ivermectin, DEC and Albendazole has been initiated in addition to ascertaining the current status of LF endemicity in non-MDA districts. Based on experience of long journey towards ELF with mix of success and challenges, it is suggested to intensify ELF in a mission mode with priority.

APA, Harvard, Vancouver, ISO, and other styles

26

Kumar, Satish. "Lymphatic Filariasis Presenting as Asymptomatic Unilateral Inguinal Swelling." Journal of Advanced Research in Medicine 06, no. 02 (September 16, 2019): 23–25. http://dx.doi.org/10.24321/2349.7181.201911.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Bhunu, C. P., and S. Mushayabasa. "Transmission Dynamics of Lymphatic Filariasis: A Mathematical Approach." ISRN Biomathematics 2012 (October 17, 2012): 1–9. http://dx.doi.org/10.5402/2012/930130.

Full text

Abstract:

An epidemiological model for the spread of lymphatic filariasis, a mosquito-borne infection, is developed and analysed. The epidemic thresholds known as the reproduction number and equilibria for the model are determined and stabilities analysed. Results from the analysis of the reproduction number suggest that treatment will somehow contribute to a reduction in lymphatic filariasis cases, but what it does not show is the magnitude of the reduction, a part answered by the numerical simulations. Numerical simulations show that even when all lymphatic filariasis cases displaying elephantiasis symptoms are put on treatment it will not be able to eradicate the disease. This result suggests that effective control of lymphatic filariasis may lie in treatment for those displaying symptoms as well as chemoprophylaxis for the exposed.

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Lymphatic filariasis: elimination a possibility?" Inpharma Weekly &NA;, no. 1368 (December 2002): 10. http://dx.doi.org/10.2165/00128413-200213680-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Leggat, Peter A., Wayne Melrose, and David N. Dürrheim. "Could It Be Lymphatic Filariasis?" Journal of Travel Medicine 11, no. 1 (January 2004): 56–60. http://dx.doi.org/10.2310/7060.2004.13636.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Kron, M., E. Walker, L. Hernandez, E. Torres, and B. Libranda-Ramirez. "Lymphatic Filariasis in the Philippines." Parasitology Today 16, no. 8 (August 2000): 329–33. http://dx.doi.org/10.1016/s0169-4758(00)01705-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Michael, E., and D. A. P. Bundy. "Global mapping of lymphatic filariasis." Parasitology Today 13, no. 12 (December 1997): 472–76. http://dx.doi.org/10.1016/s0169-4758(97)01151-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Ndeffo-Mbah, Martial L., and Alison P. Galvani. "Global elimination of lymphatic filariasis." Lancet Infectious Diseases 17, no. 4 (April 2017): 358–59. http://dx.doi.org/10.1016/s1473-3099(16)30544-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Samykutty, Abhilash, Gajalakshmi Dakshinamoorthy, and Ramaswamy Kalyanasundaram. "Multivalent Vaccine for Lymphatic Filariasis." Procedia in Vaccinology 3 (2010): 12–18. http://dx.doi.org/10.1016/j.provac.2010.11.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Fischer, Peter. "Developments in lymphatic filariasis research." Trends in Parasitology 18, no. 1 (January 2002): 48. http://dx.doi.org/10.1016/s1471-4922(01)02195-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Maher, Dermot, and Eric A. Ottesen. "The Global Lymphatic Filariasis Initiative." Tropical Doctor 30, no. 3 (July 2000): 178–79. http://dx.doi.org/10.1177/004947550003000324.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Padhi, N., KG Achary, SK Kar, and NN Mandal. "P44 Arthritis in lymphatic filariasis." Indian Journal of Rheumatology 5, no. 3 (November 2010): S24. http://dx.doi.org/10.1016/s0973-3698(10)60658-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Bockarie, M. J., and D. H. Molyneux. "The end of lymphatic filariasis?" BMJ 338, may13 1 (May 13, 2009): b1686. http://dx.doi.org/10.1136/bmj.b1686.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

BROWN, K. R., F. M. RICCI, and E. A. OTTESEN. "Ivermectin: effectiveness in lymphatic filariasis." Parasitology 121, S1 (October 2000): S133—S146. http://dx.doi.org/10.1017/s0031182000006570.

Full text

Abstract:

This detailed review of the published studies underlying ivermectin's recent registration for use in lymphatic filariasis (LF) demonstrates the drug's single-dose efficacy (over the range of 20–400μg/kg) in clearing microfilaraemia associated with both Wuchereria bancrofti and Brugia malayi infections of humans. While doses as low as 20μg/kg could effect transient microfilarial (mf) clearance, higher dosages induced greater and more sustained mf reduction. The single dose of 400μg/kg yielded maximal responses, but a number of practical considerations suggest that either 400μg/kg or 200μg/kg doses would be acceptable for use in LF control programmes. Associated safety assessments indicate that adverse events, which occur commonly following treatment of microfilaraemic individuals, develop not because of drug toxicity but because of host inflammatory responses to dying microfilariae killed by the ivermectin treatment. Ivermectin is, therefore, a highly effective and generally well tolerated microfilaricide that may soon become an essential component of many public health initiatives to interrupt transmission of lymphatic filarial infection in an effort to eliminate LF globally.

APA, Harvard, Vancouver, ISO, and other styles

39

Grady, Caroline A., Madsen Beau de Rochars, Abdel N. Direny, Jean Nicolas Orelus, Joyanna Wendt, Jeanne Radday, Els Mathieu, et al. "Endpoints for Lymphatic Filariasis Programs." Emerging Infectious Diseases 13, no. 4 (April 2007): 608–10. http://dx.doi.org/10.3201/eid1304.061063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Kazura, James W. "Ivermectin and human lymphatic filariasis." Microbial Pathogenesis 14, no. 5 (May 1993): 337–42. http://dx.doi.org/10.1006/mpat.1993.1033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Bockarie, Moses J. "Molecular Xenomonitoring of Lymphatic Filariasis." American Journal of Tropical Medicine and Hygiene 77, no. 4 (October 1, 2007): 591–92. http://dx.doi.org/10.4269/ajtmh.2007.77.591.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

&NA;. "Global alliance targets lymphatic filariasis." Inpharma Weekly &NA;, no. 1223 (February 2000): 4. http://dx.doi.org/10.2165/00128413-200012230-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Sheik, Yasmeen, Sameera Fatima Qureshi, Basheeruddin Mohhammed, and Pratibha Nallari. "FOXC2andFLT4Gene Variants in Lymphatic Filariasis." Lymphatic Research and Biology 13, no. 2 (June 2015): 112–19. http://dx.doi.org/10.1089/lrb.2014.0025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Thami, G. P. "Lymphatic filariasis--lest we forget." Sexually Transmitted Infections 76, no. 4 (August 1, 2000): 321. http://dx.doi.org/10.1136/sti.76.4.321.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Arora, Vinod K., Navjeevan Singh, and Arati Bhatia. "Cytomorphologic Profile of Lymphatic Filariasis." Acta Cytologica 40, no. 5 (1996): 948–52. http://dx.doi.org/10.1159/000334006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Nutman, Thomas B. "Protective immunity in lymphatic filariasis." Experimental Parasitology 68, no. 2 (February 1989): 248–52. http://dx.doi.org/10.1016/0014-4894(89)90106-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Weil, Gary J. "Parasite antigenemia in lymphatic filariasis." Experimental Parasitology 71, no. 3 (October 1990): 353–56. http://dx.doi.org/10.1016/0014-4894(90)90042-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Kapil, Aruna. "Laboratory diagnosis of lymphatic filariasis." Indian Journal of Pediatrics 56, no. 3 (May 1989): 314–17. http://dx.doi.org/10.1007/bf02722290.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Hyma, B., A. Ramesh, and K. Gunesekaran. "Lymphatic filariasis in Madras, India." Social Science & Medicine 29, no. 8 (January 1989): 983–90. http://dx.doi.org/10.1016/0277-9536(89)90054-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

deVries, CatherineR. "Basic science of lymphatic filariasis." Indian Journal of Urology 21, no. 1 (2005): 5. http://dx.doi.org/10.4103/0970-1591.19542.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Lymphatic filariasis'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles